



MINISTRY  
OF HEALTH



# 9<sup>th</sup> WBMT SYMPOSIUM

An international scientific convention in collaboration with  
The First Central Hospital of Mongolia and the Ministry of Health, Government of Mongolia



**28 June 2025 • Holiday Inn Hotel Ulaanbaatar**

Ulaanbaatar, Mongolia | Hybrid

<https://wbmt2025symposium.com>



## Welcome Note

The Worldwide Network for Blood and Marrow Transplantation (WBMT) is incorporated as a non-profit organization for educational, scientific and philanthropic purposes under the laws of Switzerland and a non-Governmental Organization in official working relations with the World Health Organization. The Network promotes excellence in Hematopoietic cell transplantation (HCT), stem cell donation, cellular therapy (CT) and accreditation as well as access to HCT worldwide through collaboration of existing international societies using coordination, communication and advocacy.

The purpose of this cooperation is to engage exclusively in charitable, scientific, and educational activities and endeavors including specifically, but not limited to, promoting and fostering among the many scientific and clinical disciplines, the exchange and diffusion of information and ideas relating to HCT and CT. The focus of the WBMT is to advance the field of HCT and CT in collaboration with its member societies by providing an excellent platform where different specialists are working together offering their decades of experience and expertise to develop and improve transplant activities in resource restricted countries.

The tools used to obtain this mission are biennial surveys, recommendations and workshops. This 9th Workshop in Mongolia will include delegates from North America, Latin-America, Asia Pacific, Eastern Mediterranean/Africa and Europe who will all be involved in discussion and guidance on establishing transplantation programs, donor selection, coordination among transplant societies and centers, transfusion support, accreditation system, cell processing and quality assurance. Regional experts will be presenting transplant activities and local health authorities will be engaged to sensitize them about the importance of HCT as a curative therapy for a variety of malignant and non-malignant disorders. The local organization of this event is headed by Prof. Dr. Khishigjaral Batsukh of Mongolia and involves many neighboring countries in the Asia-Pacific, European and East-Mediterranean Region.

We are delighted to welcome our friends and participants from all over the world to this prestigious event. We hope that this event will increase knowledge, skill, networking with new friends and colleagues and last but not the least, to enjoy the Mongolian culture and hospitality. On behalf of the organizing committee, we welcome you all to the 9th WBMT Workshop in Ulaanbaatar. This represents a historical event involving global experts, who are known for their efforts to improve health care access and treatment throughout the World.



**Damiano Rondelli, MD**  
WBMT President

## Welcome Address

from the President of the Local Organizing Committee

We are pleased to welcome you to the 9th WBMT SYMPOSIUM, which takes place on June 28, 2025, in the esteemed locale of Ulaanbaatar, Mongolia.

The local organization of this event is done by the First Central Hospital of Mongolia. Established in 1925. In 2010, we embarked on an ambitious journey to establish a Bone Marrow Transplantation (BMT) program. This program saw its first milestone in 2014 with the successful completion of our first autologous transplant and we achieved another milestone in 2022 with our first allogeneic transplant.

Recognizing the importance of advancing our BMT services, we are now aiming to take the next step in our development. Our goal is to enhance our capacities and extend our services to include pediatric bone marrow transplantation. This initiative is a testament to our commitment to providing comprehensive and inclusive care for all age groups.

The workshop endeavors to serve as a distinguished forum, facilitating attendees in acquainting themselves with refined and efficacious methodologies and approaches in hematopoietic stem cell transplantation. With great assurance, we anticipate that this gathering will provide a comprehensive platform for the acquisition of fresh insights, the honing of skills, and the collaborative resolution of pertinent challenges within the discipline.

The 9th WBMT WORKSHOP is poised to be an instructive, and unforgettable occasion, uniting leading authorities to exchange their wealth of experiences and perspectives. We extend a heartfelt invitation to all esteemed professionals engaged in the realm of hematopoietic stem cell transplantation to converge in Ulaanbaatar, the distinguished capital of Mongolia, for this stimulating workshop.

We cordially extend this invitation to join us at the 9th WBMT CONGRESS, eagerly anticipating an enriching and productive interchange of ideas.



**Prof. Dr. Khishigjargal Batsukh**

Co-Chairperson

9th WBMT Congress Organizing Committee

## About the Congress

### What is the purpose of the congress?

It is our goal to guide physicians to optimize their current stem cell transplantation activities and to create awareness among policy makers about the value of stem cell transplantation, so that these activities might be expanded as part of national health plan and strengthened by ongoing effective oversight and support from health authorities. The overall objective is to assist Mongolia and other countries by building capacity, increasing access to life-saving therapies, and improving the quality of care.

Additionally, the Symposium can offer sponsors in the pharmaceutical sector new opportunities in medicine in general, with a more detailed focus on hematological diagnostics and medications used in stem cell transplantation.

### Who is attending the congress?

The Congress of the WBMT is addressed to clinicians and representatives of health authorities from Mongolia, as well as other neighboring countries that may have restricted sources and low transplant participants regarding minimum essential requirements for establishing or expanding HSCT in emerging countries, indications for HSCT, training and dissemination of knowledge, stem cell donor selection and donor safety, quality assurance in transplant centers and the importance of transplant outcome databases.

### Who is WBMT?

The WBMT is a non-profit organization of twenty-one international societies involved in hematopoietic stem cell transplantation (HSCT) around the world, with a primary mission of establishing broad standards and assisting countries with limited resources in planning, development, and performance of this activity.

The purpose of this cooperation is to engage exclusively in charitable, scientific, and educational activities and endeavors by promoting and fostering the exchange and diffusion of information and ideas relating to HCT and CT and encouraging investigations on these matters. The focus of the Network is to collaboratively advance the field of HCT and CT while not pre-empting the activities of its member societies.

9<sup>th</sup> WBMT SYMPOSIUM PROGRAM  
28 June 2025 • Holiday Inn Hotel Ulaanbaatar • Mongolia – Hybrid

**SYMPOSIUM PROGRAM. Saturday, 28 June 2025**

Time	Topic Title / Activity	Chairs /Speakers /Moderators
<b>Session I:</b>	<b>Transplant Strategies in 2025</b>	<i>Chairpersons:</i> <b>Damiano Rondelli (USA)</b> <b>Batsukh Khishigjargal (Mongolia)</b>
8.30 AM - 8.50 AM	<b>Indication for HCT</b>	<b>Marcelo Pasquini* (USA)</b> <b>Carmem Bonfim* (USA)</b>
8.50 AM - 9:10 AM	<b>Optimal conditioning regimens for HCT</b>	<b>Dietger Niederwieser* (USA)</b>
9:10 AM - 9:30 AM	<b>Role of Haploidentical HCT</b>	<b>Sebastian Galeano (Uruguay)</b>
9:30 AM - 9:45 AM	<b>Optimal GvHD prophylaxis</b>	<b>Damiano Rondelli (USA)</b>
9:45 AM - 10:15 AM	Panel discussion:	<b>Marcelo Pasquini* (USA)</b> <b>Carmem Bonfim* (USA)</b> <b>Dietger Niederwieser* (USA)</b> <b>Sebastian Galeano (Uruguay)</b>
10:15 AM - 10:30 AM	Coffee Break	
<b>Session II:</b>	<b>HCT in Hematological Malignancies</b>	<i>Chairpersons:</i> <b>Daniel Weisdorf (USA)</b> <b>Saruul Tungalag (Mongolia)</b>
10:30 AM - 10:45AM	<b>Myeloid malignancies (AML/MDS)</b>	<b>Dietger Niederwieser* (USA)</b>
10:45 AM - 11:00 AM	<b>Multiple Myeloma</b>	<b>Laurent Garderet (France)</b>
11:00 AM - 11:15 AM	<b>Lymphoma and ALL</b>	<b>Sebastian Galeano (Uruguay)</b>
11:15 AM - 11:30 AM	Panel discussion:	<b>Dietger Niederwieser* (USA)</b> <b>Laurent Garderet (France)</b> <b>Sebastian Galeano (Uruguay)</b>
	<b>Graft versus Host Disease Update</b> (made possible by an unrestricted educational grant from Therakos)	<i>Moderator:</i> <b>Damiano Rondelli (USA)</b>
11:30 AM – 11:50 PM	<b>Acute and Chronic GvHD</b>	<b>Dietger Niederwieser* (USA)</b>
11:50 AM – 12:10 PM	<b>Therapy of acute and chronic GvHD</b>	<b>Hildegard Greinix* (Austria)</b>
12:10 PM – 12:30 PM	<b>Technical aspects in ECP</b> (e.g. venous access, anticoagulation)	<b>Nina Worel (Austria)</b>
12:30 PM – 1:10 PM	LUNCH	
<b>Session III:</b>	<b>HCT in non-malignant diseases</b>	<i>Chairpersons:</i> <b>Yoshihisa Kodera (Japan)</b> <b>Otgonbat Altangerel (Mongolia)</b>
1:10 PM - 1:25 PM	<b>HCT in bone marrow failures</b>	<b>Damiano Rondelli (USA)</b>
1:25 PM - 1:40 PM	<b>HCT in thalassemia SCD</b>	<b>Suradej Hongeng (Thailand)</b>
1:40 PM - 2:05 PM	<b>HCT in immunodeficiency disorders</b>	<b>Carmem Bomfim* (USA)</b>
2:05 PM - 2:35 PM	Panel discussion:	<b>Damiano Rondelli (USA)</b> <b>Suradej Hongeng (Thailand)</b> <b>Carmem Bomfim* (USA)</b>
2:35 PM – 2:50 PM	Coffee Break	

<b>Session IV</b>	<b>Complications of HCT</b>	<i>Chairpersons:</i> <b>Marcelo Pasquini*</b> (USA) <b>Oyundelger Norov</b> (Mongolia)
2:50 PM - 3:05 PM	<b>Management of Graft Failure</b>	<b>Sebastian Galeano</b> (Uruguay)
3:05 PM - 3:20 PM	<b>Management of steroid refractory acute and chronic GvHD</b>	<b>Damiano Rondelli</b> (USA)
3:20 PM - 3:35 PM	<b>Managing relapse after allogeneic HCT</b>	<b>Suradej Hongeng</b> (Thailand)
3:35 PM - 4:05 PM	<b>Early follow up: homecare of post-transplant patient in limited resource country</b>	<b>Adriana Seber</b> (Brazil)
4:05 PM - 4:35 PM	Panel discussion:	<b>Sebastian Galeano</b> (Uruguay) <b>Damiano Rondelli</b> (USA) <b>Suradej Hongeng</b> (Thailand) <b>Adriana Seber</b> (Brazil)
<b>Session V:</b>	<b>Emerging immunotherapies in Hematological Malignancies</b>	<i>Chairpersons:</i> <b>Dietger Niederwieser*</b> (USA) <b>Narangerel Jigjidkhorloo</b> (Mongolia)
4:35 PM - 4:50 PM	<b>CAR-T or bispecific antibodies in NHL</b>	<b>Mickey Koh</b> (UK)
4:50 PM - 5:05 PM	<b>Implementing a CAR T program in LowMiddle Income countries: Essential elements and considerations</b>	<b>Abdulwahab Albabtain</b> (Saudi Arabia)
5:05 PM - 5:35 PM	Panel discussion:	<b>Mickey Koh</b> (UK) <b>Abdulwahab Albabtain</b> (Saudi Arabia)
5:35 PM - 5:45 PM	<b>Closing remarks</b>	<b>Damiano Rondelli</b> (USA)

\*Virtual speakers





# The global No. 1 in **Stem Cell deliveries**

We are the worldwide leader in  
organizing accompanied transport  
for stem cell transplants.



**LIFECOURIERS.COM**



## Thank you to our sponsors!



This event is organized in accordance with international compliance standards governing interactions with healthcare professionals. All hospitality and benefits are appropriate, moderate, and solely related to the educational purpose of the meeting.

Participants are responsible for ensuring compliance with their local regulations and employer policies.



**:medac**

**MADE  
FOR  
MORE**

## **TRECONDI®**

- Highly effective in terms of OS and EFS with low toxicity and low NRM\*
- The only treosulfan approved in Europe for conditioning prior to alloHSCT



**TRECONDI®**  
TREOSULFAN

IMPROVING PERSPECTIVES

\* Based on medac's clinical trial programme:  
Beelen DW et al. Am J Hematol. 2022;97(8):1023-1034  
Casper J et al. Bone Marrow Transplant. 2012;47(9):1171-1177  
Kalwak K et al. Bone Marrow Transplant. 2020;55(10):1996-2007  
Ruutu T et al. Haematologica. 2011;96(9):1344-1350



